PFIZER INC.

The 'Idiopathic Inflammatory Myositis - Market Insights, Epidemiology, and Forecast to 2034' report by ResearchAndMarkets.com provides an in-depth analysis of the market, epidemiology, and emerging therapies for idiopathic inflammatory myositis. Key highlights include the projected growth of the market driven by innovative therapies like dazukibart and efgartigimod, the rising prevalence of cases, and the market size of approximately USD 447 million in 2023, expected to grow at a CAGR of 21.1% by 2034. The report also covers current treatment practices, unmet medical needs, and market share by therapies in the 7MM (US, EU4, UK, Japan).

DelveInsight's report on PD-1 Non-Small Cell Lung Cancer Market (2020-2034) highlights market growth, approvals, prevalence, therapies, and companies like Merck, Bristol-Myers Squibb, Genentech, and others. Key therapies include KEYTRUDA, OPDIVO, TECENTRIQ, and TIZVENI. Market drivers include premium-priced targeted agents and therapy expansion, while barriers include premium pricing of emerging therapies.

The global oncology-based in-vivo CRO market was valued at USD 1.4 billion in 2024 and is expected to grow at an 8.8% CAGR from 2025 to 2034, driven by demand for immuno-oncology therapies, advancements in in-vivo models, and growing oncology drug approvals from small biotech and pharmaceutical companies. Small firms lead in oncology drug approvals, focusing on innovative treatments like CAR-T cell therapy and monoclonal antibodies. The market is segmented by service, model, end use, and region, with preclinical testing dominating. Key trends include the rise of immunotherapies, outsourcing by biotech firms, AI integration, and strategic alliances between companies and CROs.

Arvinas and Pfizer report preliminary Phase Ib trial results of vepdegestrant plus abemaciclib for ER+/HER2- breast cancer, showing a 62.5% clinical benefit rate and a tolerable safety profile.

The FcRn inhibitor market report by ResearchAndMarkets.com provides insights into historical and competitive landscapes, market trends, emerging drugs, and forecasts from 2020 to 2034. Key players like Johnson & Johnson, UCB Biopharma, Pfizer, and Immunovant are developing FcRn inhibitors for autoimmune diseases. Prominent drugs include VYVGART, RYSTIGGO, and batoclimab, with positive trial results and FDA approvals. The market is expected to grow due to increasing diagnoses and emerging therapies.

At the 2024 San Antonio Breast Cancer Symposium, experts discussed FDA approvals for ribociclib and inavolisib in HR+/HER2- BC, emphasizing treatment optimization, clinical trial design, and addressing ovarian/reproductive toxicities. Ribociclib's approval was based on NATALEE trial data showing improved invasive disease-free survival (iDFS) with safety concerns. Inavolisib, targeting PIK3CA mutations, showed improved progression-free survival (PFS) with post-marketing commitments for further evaluation. The session highlighted the need for comprehensive data analysis and monitoring of fertility impacts.

2024 saw significant progress in digital health, particularly in AI adoption, as healthcare navigated economic shifts and technological advancements. Moving into 2025, AI will continue to accelerate in clinical workflows but face added scrutiny for quality and safety. Misinformation will persist, challenging public trust, while digital health companies can help rebuild it through transparency and education. Healthcare M&A is expected to increase with reduced FTC scrutiny, and pharma pricing and PBMs will remain under pressure. Medicaid will see a partisan split, with red states potentially reducing expansion and blue states increasing coverage. The dementia crisis will be addressed through digital innovations like the GUIDE program, and biopharma will focus more on consumer engagement and retention. Overall, 2025 is poised for continued innovation in digital health despite regulatory uncertainties.

A review in *Blood Cancer Discovery* outlines a major multiple myeloma research project that supported the FDA's decision to greenlight minimal residual disease (MRD) as a biomarker endpoint for accelerated drug approval, potentially cutting a decade off the drug development process. The research, led by C. Ola Landgren and Sean Devlin, examined how MRD measurements correlate with clinical outcomes, leading to the FDA committee's 12-0 vote in April 2024 to allow MRD as a clinical trial endpoint for accelerated approval in multiple myeloma.

Arvinas and Pfizer announced preliminary Phase 1b data showing 62.5% clinical benefit rate for vepdegestrant plus abemaciclib in advanced breast cancer patients previously treated with CDK4/6 inhibitors. The combination demonstrated a tolerable safety profile and no significant drug-drug interaction. Data will be presented at the 2024 San Antonio Breast Cancer Symposium.

Kelly Chibale's vision for an African drug discovery network, initiated 20 years ago, has materialized into the Grand Challenges African Drug Discovery Accelerator (GC-ADDA), supported by the Bill & Melinda Gates Foundation and LifeArc. The network focuses on four flagship projects across Africa, addressing malaria, TB, drug metabolism, and natural product research, aiming to combat antimicrobial resistance and support local API manufacturing.